(PRAX) Praxis Precision Medicines - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 9.356m USD | Total Return: 796.8% in 12m
Avg Turnover: 118M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Share dilution 37.2% YoY
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
Leader, Tailwind
Ticker Symbol: PRAX Type: common stock Country of Origin: United States GICS Sub Industry: Biotechnology
Praxis Precision Medicines is a clinical-stage biopharmaceutical firm focused on central nervous system (CNS) disorders. The company utilizes two primary development platforms: Cerebrum for small molecule discovery and Solidus for antisense oligonucleotide (ASO) development. Its late-stage pipeline includes ulixacaltamide for essential tremor and several candidates targeting developmental and epileptic encephalopathies (DEE), such as relutrigine and vormatrigine. The business model relies on genetic validation to target neuronal excitation-inhibition imbalances, a strategy common in precision medicine to reduce clinical failure rates.
The CNS therapeutic sector faces high barriers to entry due to the complexity of the blood-brain barrier and the rigorous regulatory requirements for neurological drugs. Praxis mitigates these developmental risks through strategic collaborations with industry partners like Ionis Pharmaceuticals and RogCon Inc. For a deeper look at how these clinical milestones impact valuation, consider reviewing the latest data on ValueRay. The company maintains its headquarters in Boston, a primary global hub for biotechnology research and venture capital investment.
- Clinical trial outcomes for ulixacaltamide in essential tremor dictate near-term valuation
- Regulatory approval of relutrigine for pediatric epilepsy remains a critical catalyst
- Strategic licensing deals with Ionis Pharmaceuticals provide long-term R&D capital
- Phase 3 data for vormatrigine determines entry into broad focal epilepsy market
- Cash runway and future equity offerings impact shareholder dilution and liquidity
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.19 > 0.02 and ΔFCF/TA 14.80 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.19 > 3% & CFO -282.7m > Net Income -326.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 15.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.9m) vs 12m ago 37.18% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 1.70%; Δ -1.70% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.51 (Total Current Assets 797.8m - Total Current Liabilities 50.2m) / Total Assets 1.46b |
| B: -0.84 (Retained Earnings -1.23b / Total Assets 1.46b) |
| C: -0.36 (EBIT TTM -352.9m / Avg Total Assets 969.5m) |
| D: -24.56 (Book Value of Equity -1.23b / Total Liabilities 50.2m) |
| Altman-Z'' = -27.63 = D |
As of May 24, 2026, the stock is trading at USD 350.56 with a total of 285,914 shares traded.
Over the past week, the price has changed by +0.29%,
over one month by +1.86%,
over three months by +0.32% and
over the past year by +796.79%.
Praxis Precision Medicines has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy PRAX.
- StrongBuy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 652.2 | 86% |
P/B = 6.6276
Revenue TTM = 0.0 USD
EBIT TTM = -352.9m USD
EBITDA TTM = -352.8m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 1.44m USD (from shortTermDebt, last quarter)
Debt = 1.44m USD (from shortLongTermDebtTotal, last quarter) (leases 1.44m already included)
Net Debt = -785.4m USD (calculated: Debt 1.44m - CCE 786.9m)
Enterprise Value = 8.57b USD (9.36b + Debt 1.44m - CCE 786.9m)
Interest Coverage Ratio = unknown (Ebit TTM -352.9m / Interest Expense TTM 0.0)
EV/FCF = -30.30x (Enterprise Value 8.57b / FCF TTM -282.9m)
FCF Yield = -3.30% (FCF TTM -282.9m / Enterprise Value 8.57b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 128.9m) / Revenue TTM)
Tobins Q-Ratio = 5.87 (Enterprise Value 8.57b / Total Assets 1.46b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.44m)
Taxrate = 21.0% (US default 21%)
NOPAT = -278.8m (EBIT -352.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.88 (Total Current Assets 797.8m / Total Current Liabilities 50.2m)
Debt / Equity = 0.00 (Debt 1.44m / totalStockholderEquity, last quarter 1.41b)
Debt / EBITDA = 2.23 (negative EBITDA) (Net Debt -785.4m / EBITDA -352.8m)
Debt / FCF = 2.78 (negative FCF - burning cash) (Net Debt -785.4m / FCF TTM -282.9m)
Total Stockholder Equity = 759.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.68% (Net Income -326.5m / Total Assets 1.46b)
RoE = -16.40% (Net Income TTM -326.5m / Total Stockholder Equity 1.99b)
RoCE = -17.72% (EBIT -352.9m / Capital Employed (Equity 1.99b + L.T.Debt 0.0))
RoIC = -20.70% (negative operating profit) (NOPAT -278.8m / Invested Capital 1.35b)
WACC = 11.39% (E(9.36b)/V(9.36b) * Re(11.39%) + D(1.44m)/V(9.36b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 67.41%
[DCF] Fair Price = unknown (Cash Flow -282.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.83 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-3.69 | Chg30d=+2.81% | Revisions=-29% | Analysts=14
EPS next Quarter (2026-09-30): EPS=-4.00 | Chg30d=-1.10% | Revisions=-14% | Analysts=14
EPS current Year (2026-12-31): EPS=-15.11 | Chg30d=+0.71% | Revisions=-7% | GrowthEPS=-12.1% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-9.85 | Chg30d=-14.49% | Revisions=+0% | GrowthEPS=+34.8% | GrowthRev=+7908.0%
[Analyst] Revisions Ratio: -29%